Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

The shortfall of risk assessment for decision-making.

Hjorth R.

Nat Nanotechnol. 2017 Dec 6;12(12):1109-1110. doi: 10.1038/nnano.2017.232. No abstract available.

PMID:
29209011
2.

Ecotoxicity testing and environmental risk assessment of iron nanomaterials for sub-surface remediation - Recommendations from the FP7 project NanoRem.

Hjorth R, Coutris C, Nguyen NHA, Sevcu A, Gallego-Urrea JA, Baun A, Joner EJ.

Chemosphere. 2017 Sep;182:525-531. doi: 10.1016/j.chemosphere.2017.05.060. Epub 2017 May 13.

PMID:
28521168
3.

What can nanosafety learn from drug development? The feasibility of "safety by design".

Hjorth R, van Hove L, Wickson F.

Nanotoxicology. 2017 Apr;11(3):305-312. doi: 10.1080/17435390.2017.1299891. Epub 2017 Mar 17. Review.

PMID:
28303735
4.

Aquatic Ecotoxicity Testing of Nanoparticles-The Quest To Disclose Nanoparticle Effects.

Skjolding LM, Sørensen SN, Hartmann NB, Hjorth R, Hansen SF, Baun A.

Angew Chem Int Ed Engl. 2016 Dec 5;55(49):15224-15239. doi: 10.1002/anie.201604964. Epub 2016 Nov 9. Review.

5.

Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.

Wahid R, Holt R, Hjorth R, Berlanda Scorza F.

Vaccine. 2016 Oct 26;34(45):5430-5435. doi: 10.1016/j.vaccine.2016.07.046. Epub 2016 Jul 30. Review.

6.

The applicability of chemical alternatives assessment for engineered nanomaterials.

Hjorth R, Hansen SF, Jacobs M, Tickner J, Ellenbecker M, Baun A.

Integr Environ Assess Manag. 2017 Jan;13(1):177-187. doi: 10.1002/ieam.1762. Epub 2016 Apr 2.

PMID:
26887668
7.

A certain shade of green: Can algal pigments reveal shading effects of nanoparticles?

Hjorth R, Sørensen SN, Olsson ME, Baun A, Hartmann NB.

Integr Environ Assess Manag. 2016 Jan;12(1):200-2. doi: 10.1002/ieam.1728. Epub 2015 Dec 3. No abstract available.

PMID:
26632196
8.

Balancing scientific tensions.

Wickson F, Hartmann NB, Hjorth R, Hansen SF, Wynne B, Baun A.

Nat Nanotechnol. 2014 Nov;9(11):870. doi: 10.1038/nnano.2014.237. No abstract available.

PMID:
25370421
9.

Uptake and depuration of gold nanoparticles in Daphnia magna.

Skjolding LM, Kern K, Hjorth R, Hartmann N, Overgaard S, Ma G, Veinot JG, Baun A.

Ecotoxicology. 2014 Sep;23(7):1172-83. doi: 10.1007/s10646-014-1259-x. Epub 2014 May 27.

10.

Dr. Peter Ebeling.

Davis S, Hjorth R, King J, Kilpatrick C.

J Clin Neurosci. 2013 May;20(5):642-3. doi: 10.1016/j.jocn.2013.02.017. Epub 2013 Apr 9. No abstract available.

PMID:
23578818
11.

DNMT1 mutation hot spot causes varied phenotypes of HSAN1 with dementia and hearing loss.

Klein CJ, Bird T, Ertekin-Taner N, Lincoln S, Hjorth R, Wu Y, Kwok J, Mer G, Dyck PJ, Nicholson GA.

Neurology. 2013 Feb 26;80(9):824-8. doi: 10.1212/WNL.0b013e318284076d. Epub 2013 Jan 30.

12.

Integration of scale-down experimentation and general rate modelling to predict manufacturing scale chromatographic separations.

Gerontas S, Asplund M, Hjorth R, Bracewell DG.

J Chromatogr A. 2010 Oct 29;1217(44):6917-26. doi: 10.1016/j.chroma.2010.08.063. Epub 2010 Sep 27.

PMID:
20880533
13.

Use of dimensionless residence time to study variations in breakthrough behaviour in expanded beds formed from varied particle size distributions.

Gardner PJ, Willoughby N, Hjorth R, Lacki K, Titchener-Hooker NJ.

Biotechnol Bioeng. 2004 Aug 5;87(3):347-53.

PMID:
15281109
14.

Hydrophobic interaction ligand selection and scale-up of an expanded bed separation of an intracellular enzyme from Saccharomyces cerevisiae.

Smith MP, Bulmer MA, Hjorth R, Titchener-Hooker NJ.

J Chromatogr A. 2002 Aug 30;968(1-2):121-8.

PMID:
12236495
15.

Stabilizing cold-adapted influenza virus vaccine under various storage conditions.

Yannarell DA, Goldberg KM, Hjorth RN.

J Virol Methods. 2002 Apr;102(1-2):15-25.

PMID:
11879689
16.
17.

Experimental measurement of particle size distribution and voidage in an expanded bed adsorption system.

Willoughby NA, Hjorth R, Titchener-Hooker NJ.

Biotechnol Bioeng. 2000 Sep 20;69(6):648-53.

PMID:
10918140
18.

Direct visualisation of plasmid DNA in individual chromatography adsorbent particles by confocal scanning laser microscopy.

Ljunglöf A, Bergvall P, Bhikhabhai R, Hjorth R.

J Chromatogr A. 1999 Jun 4;844(1-2):129-35.

PMID:
10399329
19.

Immobilised metal ion affinity chromatography purification of alcohol dehydrogenase from baker's yeast using an expanded bed adsorption system.

Willoughby NA, Kirschner T, Smith MP, Hjorth R, Titchener-Hooker NJ.

J Chromatogr A. 1999 Apr 30;840(2):195-204.

PMID:
10343398
20.

Expanded-bed adsorption in industrial bioprocessing: recent developments.

Hjorth R.

Trends Biotechnol. 1997 Jun;15(6):230-5. Review.

PMID:
9183866
21.

The effect of Syntex adjuvant formulation (SAF-m) on humoral immunity to the influenza virus in the mouse.

Hjorth RN, Bonde GM, Piner ED, Goldberg KM, Levner MH.

Vaccine. 1997 Apr;15(5):541-6.

PMID:
9160522
22.

Factors affecting the yield of cold-adapted influenza virus vaccine.

Yannarell DA, Hjorth RN.

J Virol Methods. 1997 Mar;64(2):161-9.

PMID:
9079762
23.

Analysis of some operating parameters of novel adsorbents for recovery of proteins in expanded beds.

Hjorth R, Kämpe S, Carlsson M.

Bioseparation. 1995 Aug;5(4):217-23.

PMID:
8541717
24.

Rapidly progressive Whipple's disease of the central nervous system.

Niekrash R, McLean C, Kaye A, Hjorth R, Desmond P, Sinicaks V, Gonzales M.

J Clin Neurosci. 1995 Apr;2(2):171-6.

PMID:
18638806
25.

Pilot scale recovery of recombinant annexin V from unclarified escherichia coli homogenate using expanded bed adsorption.

Barnfield Frej AK, Hjorth R, Hammarström A.

Biotechnol Bioeng. 1994 Oct;44(8):922-9.

PMID:
18618910
26.

Relevance of the guinea-pig necrotic inflammation footpad reaction to safety concerns with MDP-based adjuvants.

Hjorth RN, Bonde GM, Piner ED, Goldberg KM, Levner MH, Hung PP.

Vaccine. 1994 Jun;12(8):687-90.

PMID:
8091845
27.

Single-step recovery of a secreted recombinant protein by expanded bed adsorption.

Hansson M, Ståhl S, Hjorth R, Uhlén M, Moks T.

Biotechnology (N Y). 1994 Mar;12(3):285-8.

PMID:
7764490
28.

Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.

Natuk RJ, Chanda PK, Lubeck MD, Davis AR, Wilhelm J, Hjorth R, Wade MS, Bhat BM, Mizutani S, Lee S, et al.

Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7777-81.

29.

A case of neurofibromatosis 2 presenting with a mononeuritis multiplex.

Kilpatrick TJ, Hjorth RJ, Gonzales MF.

J Neurol Neurosurg Psychiatry. 1992 May;55(5):391-3.

30.

Growth of transformed C-127 cell in bioreactors for large-scale T-PA production.

McKillip ER, Giles AS, Levner MH, Hung PP, Hjorth RN.

Biotechnology (N Y). 1991 Sep;9(9):805-6, 808, 810. No abstract available.

PMID:
1369332
31.

A new hamster model for adenoviral vaccination.

Hjorth RN, Bonde GM, Pierzchala WA, Vernon SK, Wiener FP, Levner MH, Lubeck MD, Hung PP.

Arch Virol. 1988;100(3-4):279-83.

PMID:
2840876
34.

Experimental neuritis induced by a mixture of neural antigens and influenza vaccines. A possible model for Guillain-Barré syndrome.

Hjorth RN, Bonde GM, Piner E, Hartzell RW, Rorke LB, Rubin BA.

J Neuroimmunol. 1984 Feb;6(1):1-8.

PMID:
6707195
35.

Purification of bovine papilloma virus by gel filtration on Sephacryl S-1000 superfine.

Hjorth R, Moreno-Lopez L.

J Virol Methods. 1982 Nov;5(3-4):151-8.

PMID:
6296176
36.

Removal of percoll from microsomal vesicles by gel filtration on sephacryl-S-1000 superfine.

Hjorth R, Pertoft H.

Biochim Biophys Acta. 1982 May 21;688(1):1-4.

PMID:
6284224
37.

A rapid method for purification of human granulocytes using percoll. A comparison with dextran sedimentation.

Hjorth R, Jonsson AK, Vretblad P.

J Immunol Methods. 1981;43(1):95-101.

PMID:
6167641
38.

The isolectins of Helix pomatia. Separation by isoelectric focusing and preliminary characterization.

Vretblad P, Hjorth R, Låås T.

Biochim Biophys Acta. 1979 Jul 25;579(1):52-61.

PMID:
465535
39.
40.

Improvement in paraplegia in vertebral Paget's disease treated with calcitonin.

Melick RA, Ebeling P, Hjorth RJ.

Br Med J. 1976 Mar 13;1(6010):627-8. No abstract available.

41.

The electromyogram in facial myokymia and hemifacial spasm.

Hjorth RJ, Willison RG.

J Neurol Sci. 1973 Oct;20(2):117-26. No abstract available.

PMID:
4356328
42.

The distribution and frequency of spontaneous fasciculations in motor neurone disease.

Hjorth RJ, Walsh JC, Willison RG.

J Neurol Sci. 1973 Apr;18(4):469-74. No abstract available.

PMID:
4699433
43.

Nerve conduction during Wallerian degeneration in the baloon.

Gilliatt RW, Hjorth RJ.

J Neurol Neurosurg Psychiatry. 1972 Jun;35(3):335-41.

44.

Effect of -propiolactone on Sendai virus.

Wainberg MA, Hjorth RN, Howe C.

Appl Microbiol. 1971 Oct;22(4):618-21.

45.

Studies with hydroxyurea. The biologic and metabolic properties of formamidoxime.

Rosenkranz HS, Hjorth R, Carr HS.

Biochim Biophys Acta. 1971 Feb 25;232(1):48-60. No abstract available.

PMID:
4930205
46.

DIRECT CURRENT COUNTERSHOCK IN CARDIAC ARRHYTHMIAS.

ROBINSON JS, SLOMAN G, HJORTH RJ, GOBLE AJ.

Med J Aust. 1965 Feb 27;1(9):289-92. No abstract available.

PMID:
14261907

Supplemental Content

Loading ...
Support Center